In Neuroscience, worldwide revenues of $2.2 billion were up 26% year over year at CER, driven by high-thirties growth in Neuromodulation and Specialty Therapies and high-teens growth in CST, all on an organic basis. SI rose 39% while RGR registered an improvement of 3% both at CER. In Medical Surgical, worldwide sales totaled $2.32 billion, marking a 25% year-over-year improvement at CER with high-thirties organic growth in SI and mid-single digit organic growth in RGR. CPV revenues were up 7% at CER to $620 million. Revenues from SHA were up 21% at CER to $787 million. CRHF sales totaled $1.48 billion, up 15% year over year at CER. In the fiscal first quarter, Cardiovascular revenues rose 15% at CER to $2.89 billion, reflecting low-twenties organic growth in SHA, mid-teens organic growth in CRHF, and high-single digit growth in CPV. The company currently generates revenues from four major segments, namely Cardiovascular Portfolio, Medical Surgical Portfolio, Neuroscience Portfolio, and Diabetes. developed market revenues totaled $2.6 billion (33% of total revenues), depicting a 20% improvement on a reported basis (up 11% on an organic basis).Р”В®merging market revenues (16% of total revenues) amounted to $1.27 billion, up 31% on a reported basis (up 25% organically). sales (51% of total revenues) rose 22% year over year on a reported basis to $4.1 billion. Medtronic PLC price-consensus-eps-surprise-chart | Medtronic PLC Quote Medtronic PLC Price, Consensus and EPS Surprise

Mdt download